A clinical trial showed comparable blood pressure (BP) lowering by valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in obese hypertensive patients. Relative to amlodipine/ hydrochlorothiazide, valsartan/hydrochlorothiazide reduced the hyperglycemic response to glucose challenge. An objective of this post hoc analysis was to determine whether this benefit extended to African Americans and whites. Treatments (160/12.5 mg of valsartan/ hydrochlorothiazide force titrated to 320/25 mg of valsartan/hydrochlorothiazide at week 4 or 12.5 mg of hydrochlorothiazide force titrated to 25 mg of hydrochlorothiazide at week 4 with 5 and 10 mg of amlodipine added at weeks 8 and 12, respectively) were administered once daily. Both treatments reduced clinic BP from baseline to all visits (P , 0.0001), regardless of race/ ethnicity (126 African Americans, 212 whites). In African Americans, there were no significant between-treatment differences in clinic or ambulatory BP lowering at weeks 8 or 16. Whites responded better to valsartan/hydrochlorothiazide. In both racial/ethnic subgroups, the addition of valsartan but not amlodipine mitigated the hyperglycemic response to hydrochlorothiazide through enhanced insulin secretion. Valsartan/hydrochlorothiazide was as effective as amlodipine/hydrochlorothiazide was in reducing BP in obese, hypertensive African Americans and better than amlodipine/hydrochlorothiazide in whites. In both racial/ethnic subgroups, the addition of valsartan to hydrochlorothiazide reduced the negative metabolic effects associated with thiazide therapy. FIGURE 2. Mean change from baseline to week 16 (last observation carried forward) in 24-hour ambulatory blood pressure by racial/ethnic and treatment group. Error bars represent SE. HCTZ, hydrochlorothiazide; MADBP, mean ambulatory DBP; MASBP, mean ambulatory SBP; V, valsartan.
INTRODUCTION
Distinct differences exist in the cardiovascular and metabolic disease risk among racial/ethnic groups, including the prevalence of hypertension and diabetes. The most recent analysis of the National Health and Nutrition Examination Survey (1999) (2000) (2001) (2002) (2003) (2004) data reported prevalence rates of hypertension and diabetes of approximately 40% and 15%, respectively, among African Americans compared with 27% and 6%, respectively, among whites. 1 The higher prevalence rates of hypertension and diabetes among African Americans may be related, in part, to hereditary differences, environmental, and dietary factors and psychosocial stressors. 2, 3 African Americans also have a very high rate of uncontrolled hypertension (67%), despite increased awareness and treatment relative to whites. 1 The management of hypertension in African Americans is further complicated by a higher prevalence of other risk factors such as obesity. Recent estimates indicate that 36% of African Americans are obese (vs 24% of whites). 4 Obesity is associated with more severe and treatment-resistant hypertension, which may be due, in part, to the increased activation of the reninangiotensin system (RAS). 5, 6 Some evidence suggests that RAS inhibitors, when administered as monotherapy, may lower blood pressure (BP) less effectively in African Americans and obese hypertensive patients 7 and that African Americans may respond better to diuretics or calcium channel blockers (CCBs) than to other antihypertensive classes. 8 For example, in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), which included .10,000 African Americans, an angiotensin-converting enzyme inhibitor was less effective than either a thiazide-type diuretic or a CCB. 9 In the BP-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial, a betablocker was found to be less effective than a CCB. 10 However, as noted in the recently updated International Society on Hypertension In Blacks (ISHIB) guidelines, the vast majority of African Americans will require multiple antihypertensive agents to achieve BP goals. 11 With the addition of an agent from an alternative/complementary antihypertensive class, the difference in treatment response to RAS blockade by race/ethnicity diminishes. [11] [12] [13] [14] [15] A commonly recommended option for the treatment of hypertension is the use of a thiazide-type diuretic in combination with a RAS inhibitor or CCB, 16, 17 although a recent analysis of data from the BP-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial suggests that the use of a RAS inhibitor as a second-line agent may not be an optimal treatment approach in African Americans. 10 From a safety perspective, thiazide-type diuretics may be associated with adverse metabolic effects, particularly in patients with obesity or dysglycemia, whereas RAS inhibitors exert favorable metabolic effects, and CCBs are generally regarded as metabolically neutral. [18] [19] [20] [21] [22] In the Valsartan and hydrochlorothiazide In hyperTensive Abdominally obEse patients (VITAE) trial, 23 valsartan/hydrochlorothiazide and amlodipine/ hydrochlorothiazide reduced BP to a similar extent in prediabetic, obese, hypertensive patients. However, of note is that valsartan but not amlodipine attenuated the adverse metabolic effects of hydrochlorothiazide; patients treated with valsartan/hydrochlorothiazide had a reduced hyperglycemic response to glucose challenge relative to patients treated with amlodipine/ hydrochlorothiazide. 23 Other studies have shown a significantly reduced risk of new-onset diabetes when valsartan was administered in combination with hydrochlorothiazide (6 other antihypertensive agents), 24 including in patients with impaired glucose tolerance. 25 These results are consistent with the metabolic profiles of these drug classes. This post hoc analysis of the VITAE trial reports clinic and ambulatory BP data, metabolic indices, and adverse events (AEs) for African American and white participants. Although the VITAE trial was not designed to compare these 2 racial/ethnic subgroups from a statistical perspective, our results provide some insight into addressing the question of whether the observed benefits of valsartan in reducing the negative metabolic effects of hydrochlorothiazide in the overall population extend to both African Americans and whites.
METHODS
The VITAE trial was a 16-week, double-blind, randomized, forced-titration study in nondiabetic patients with hypertension and abdominal obesity. The methods have been published elsewhere 23 and are briefly summarized here. This study was conducted according to the Declaration of Helsinki. The study protocol was approved by the institutional review board at each site, and all the patients provided written informed consent.
Patients
The study enrolled hypertensive outpatient men and women aged 40 years or more with central obesity (in men, waist circumference .40 in/102 cm; in women, .35 in/89 cm) and mean clinic sitting systolic BP (SBP) $150 mm Hg but ,180 mm Hg and mean clinic sitting diastolic BP (DBP) ,110 mm Hg.
Key exclusion criteria were as follows: patients on .3 antihypertensive medications at the time of screening; patients unable to discontinue all prior antihypertensive medications safely during the washout phase; patients experiencing weight loss .10 lb (4.5 kg) during the screening/washout phase; or patients with a documented history of type 1 or 2 diabetes or fasting plasma glucose $126 mg/dL at screening. Other exclusion criteria included a history of pancreatic injury, pancreatitis, or impaired pancreatic function; life-threatening arrhythmia or symptomatic arrhythmia, chronic heart failure, or secondary hypertension; renal or hepatic disease, gout, malignancy, or severe autoimmune disease; and a serum potassium level ,3.5 or .5.5 mEq/L at screening. Patients were also excluded if, within the month before screening, they had unstable angina pectoris or coronary artery disease requiring treatment with nitroglycerin or if, within the 6 months before screening, they had significant coronary artery disease or atherosclerotic vascular disease, stroke, transient ischemic attack, or myocardial infarction. Also excluded were female patients who were pregnant, nursing, or at a risk of becoming pregnant.
Study design
Eligible patients were randomized to either 160/12.5 mg of valsartan/hydrochlorothiazide or 12.5 mg of hydrochlorothiazide alone, after a washout phase of up to 4 weeks. At week 4, doses were force titrated to 320/25 mg of valsartan/hydrochlorothiazide and 25 mg of hydrochlorothiazide in their respective groups. At weeks 8 and 12, the patients in the valsartan/hydrochlorothiazide group remained at the same dose (320/25 mg), whereas the patients in the hydrochlorothiazide group received add-on 5 and 10 mg of amlodipine at weeks 8 and 12, respectively. Thus, from the start of the treatment through week 8, the patients received either combination therapy with valsartan/hydrochlorothiazide or monotherapy with hydrochlorothiazide. From week 8 onward, all the patients received combination therapy (valsartan/hydrochlorothiazide or amlodipine/hydrochlorothiazide). Downward titration of study drug doses was not permitted. All medications were taken once daily at the same time each morning.
Blood pressure assessments
At baseline and every 4 weeks thereafter, the BP was measured to the nearest millimeter of mercury using a sphygmomanometer and an arm cuff with dimensions adjusted according to arm circumference. The measurements were performed at trough (ie, 24 hours after the last administration of the study drug) and with the patients sitting for $5 minutes. The BP was recorded 3 times, $2 minutes apart, and the average was used for analyses. The arm with the highest BP at enrollment was used for all the subsequent measures.
Ambulatory BP measures were studied in a subset of patients. Twenty-four-hour ambulatory BP monitoring (ABPM) was conducted using a standard device (Model 90207, Spacelabs Healthcare, Issaquah, WA) at baseline, week 8, and week 16. Mean hourly ambulatory SBP and DBP were calculated for each patient at 1-24 postdosing hours. Each patient's postdosing hours were determined relative to that patient's dosing time.
Metabolic parameters
An oral glucose tolerance test (OGTT) was performed at baseline and week 16 after an overnight fast to assess fasting and postprandial glucose and insulin levels. The insulinogenic index, an assessment of the insulin response relative to a glucose load, was also determined. 26 For the OGTT, plasma samples were measured at 0, 30, 60, 90, and 120 minutes after a 75-g glucose load, which was given in a fluid volume of 250-300 mL and orally consumed within a 5-minute period.
Adverse events
All observed or volunteered AEs, including serious AEs, were recorded throughout the study period. Physical examinations were performed at screening, baseline, week 4, week 8, week 12, and study end (week 16 or discontinuation). Serum potassium was measured at baseline and at the end of the study.
Statistical analyses
All results are summarized by race/ethnicity (African Americans, whites) using the intent-to-treat population. Descriptive and inferential analyses were performed for baseline demographics and for changes in BP and metabolic parameters. All statistical tests were conducted under a 2-sided alternative hypothesis, employing a significance level of 0.05. Baseline demographic characteristics were summarized and, within each racial/ethnic subgroup, a 2-sample t-test (continuous variables) or chi-squared test (categorical variables) was used to test for homogeneity between the 2 treatment groups.
To compare changes in BP and metabolic parameters between the 2 treatment groups within each racial/ ethnic subgroup, an analysis of covariance was used with baseline assessment as a covariate and treatment as factor in the model. A t-test was used to assess the 
RESULTS

Baseline characteristics
Demographic and clinical characteristics are shown by race/ethnicity and treatment group in Table 1 . A 
Clinic blood pressure
Clinic MSSBP and MSDBP values are shown by race/ethnicity and treatment group over the course of the study in Figure 1 . For both MSSBP and MSDBP, significant (P , 0.0001) mean reductions from baseline to all study visits were observed within each of the treatment groups, regardless of race/ethnicity. In African Americans, the least-squares mean 6 standard error (SE) reduction in MSSBP from baseline to week 8 (ie, before the addition of amlodipine in the hydrochlorothiazide group) was comparable in the valsartan/hydrochlorothiazide and hydrochlorothiazide groups (225.0 6 2.0 vs 221.6 6 2.0 mm Hg; P = 0.25). Similarly, no significant difference was observed between reductions in valsartan/hydrochlorothiazide vs amlodipine/hydrochlorothiazide at week 16 (227.8 6 2.0 vs 229.3 6 2.0 mm Hg; P = 0.59). In whites, the least-squares mean 6 SE reduction in MSSBP from baseline favored valsartan/hydrochlorothiazide vs hydrochlorothiazide at week 8 (231.6 6 1.3 vs 222.1 6 1.3 mm Hg; P , 0.0001) and valsartan/hydrochlorothiazide vs amlodipine/hydrochlorothiazide at week 16 (233.0 6 1.3 vs 229.0 6 1.3 mm Hg; P = 0.027). Among the patients treated with valsartan/hydrochlorothiazide, MSSBP and MSDBP reductions from baseline to week 16 were numerically greater in whites than African Americans, whereas among patients treated with amlodipine/hydrochlorothiazide, the reductions were similar in both racial/ ethnic subgroups (Fig. 1) .
Ambulatory blood pressure
ABPM results support the clinic BP findings. ABPM was conducted in a subset of patients (33 African Americans, 57 whites). In African Americans, mean 6 SE reductions from baseline in 24-hour mean ambulatory SBP/DBP were similar in the valsartan/hydrochlorothiazide and hydrochlorothiazide groups at week 8 (215.0 6 4.6/29.7 6 3.6 vs 210.4 6 3.7/ 26.4 6 3.0 mm Hg; P = 0.53/P = 0.38) and valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide groups at week 16 (Fig. 2) . In whites, the mean 6 SE reductions from baseline in 24-hour ambulatory SBP/DBP were significantly greater with valsartan/hydrochlorothiazide vs hydrochlorothiazide at week 8 (219.1 6 2.2/29.5 6 1.3 vs 23.5 6 1.9/ 21.3 6 1.1 mm Hg; P , 0.0001) and with valsartan/ hydrochlorothiazide vs amlodipine/hydrochlorothiazide at week 16 (Fig. 2) . Among the patients treated with valsartan/hydrochlorothiazide, ambulatory BP reductions from baseline to week 16 were slightly greater in whites than in African Americans, whereas among the patients treated with amlodipine/hydrochlorothiazide, the reductions tended to be numerically greater in African Americans than in whites.
Blood pressure goal
Clinic BP goal (,140/90 mm Hg) results were consistent with the above findings. The proportion of African Americans achieving the clinic BP goal was not significantly different between valsartan/ hydrochlorothiazide vs hydrochlorothiazide at week 8 (60.0% vs 55.6%; P = 0.64) or between valsartan/ hydrochlorothiazide vs amlodipine/hydrochlorothiazide at week 16 (67.3% vs 80.4%; P = 0.13). The proportion of whites achieving the same clinic BP goal was significantly greater with valsartan/ hydrochlorothiazide vs hydrochlorothiazide at week 8 (79.3% vs 52.5%; P , 0.0001); no significant difference was seen between valsartan/hydrochlorothiazide vs amlodipine/hydrochlorothiazide at week 16 (76.7% vs 78.8%; P = 0.75).
Metabolic parameters
Changes from baseline to the end of the study in fasting plasma glucose and insulin levels are shown in Table 2 . In African Americans, the only significant finding was that the increase in fasting plasma glucose level was 5.8 mg/dL greater in the amlodipine/hydrochlorothiazide group than in the valsartan/hydrochlorothiazide group (P = 0.049 for least-squares mean difference). In whites, the mean fasting insulin level in the amlodipine/hydrochlorothiazide group increased by 4.4 mU/mL from baseline to the end of the study (P = 0.040). No other significant findings were observed in either racial/ethnic subgroup ( Table 2) .
Mean postprandial glucose and insulin levels after OGTT are shown in Figures 3A and B , respectively. In African Americans and whites, mean postprandial glucose levels after OGTT increased more from baseline in patients receiving amlodipine/hydrochlorothiazide compared with those receiving valsartan/hydrochlorothiazide, with some of the between-treatment group differences being statistically significant (P , 0.05) (Fig. 3A) . The reduced hyperglycemic response associated with valsartan/hydrochlorothiazide therapy was due to an early increase in postprandial insulin levels in both racial/ethnic subgroups (Fig. 3B) .
The early insulin response, as reflected by insulinogenic index, was similar in both racial/ethnic subgroups. At 30 minutes, there was a greater mean increase in insulinogenic index from baseline in the valsartan/hydrochlorothiazide group [0.7-0.9 (mU/mL)/(mg/dL)] across racial/ethnic subgroups] 
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American Journal of Therapeutics (2013) 20 (1) than in the amlodipine/hydrochlorothiazide group [0.1-0.2 (mU/mL)/(mg/dL)]. In both racial/ethnic subgroups, the results were consistent with those observed in the overall population.
Adverse events
All the patients who received at least 1 dose of the study medication were included in the safety analysis. Throughout the entire study, AEs were experienced by 42.1% of the African Americans. The most frequent AEs in this racial/ethnic subgroup ($5% in either treatment group) were upper respiratory tract infection (1.5% valsartan/hydrochlorothiazide, 8.5% amlodipine/ hydrochlorothiazide), peripheral edema (3.0%, 6.8%), and constipation (0%, 5.1%). AEs were reported by 50.0% of the whites during the study, the most common of which were peripheral edema (1.0% valsartan/ hydrochlorothiazide, 14.7% amlodipine/hydrochlorothiazide), upper respiratory tract infection (2.9%, 7.3%), dizziness (6.8%, 0.9%), fatigue (5.8%, 3.7%), and rash (2.9%, 5.5%). The only reports of hypokalemia (.20% decrease) occurred in 4 (3.7%) whites treated with amlodipine/hydrochlorothiazide.
DISCUSSION
In this post hoc analysis of VITAE, the BP-lowering effect of the combination valsartan/hydrochlorothiazide was similar to that of amlodipine/hydrochlorothiazide in prediabetic, obese, hypertensive African Americans, with both regimens producing significant (P , 0.0001) reductions in MSSBP/MSDBP from baseline to all time points and high rates of BP control (,140/90 mm Hg) at week 16. Both treatments significantly (P , 0.001) reduced 24-hour ambulatory SBP/DBP from baseline to week 16 in the subset of African Americans in whom ABPM was performed. We did not perform any statistical testing for racial/ethnic differences because our study was not designed to make such comparisons. However, although the antihypertensive effects (both clinic and ABPM) of valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide were similar in African Americans, valsartan/hydrochlorothiazide provided significantly better BP-lowering efficacy than did amlodipine/ hydrochlorothiazide in whites. The superiority of an angiotensin receptor blocker (ARB)/hydrochlorothiazide combination over amlodipine/hydrochlorothiazide was previously shown in ABPM studies involving predominantly white hypertensive populations. 27, 28 Despite the apparent reduced BP benefit of valsartan/ hydrochlorothiazide in African Americans vs whites in our study, the addition of valsartan was similarly able to lessen the hyperglycemic response to hydrochlorothiazide in both racial/ethnic subgroups through enhanced insulin secretion. Amlodipine had no such effect. Sowers et al 23 previously reported this observation for the overall population. The widespread use of RAS inhibitors in African Americans has been impeded by evidence of smaller BP reductions when used as monotherapy or in the absence of a diuretic in African Americans vs whites in some studies. 29 However, the importance of racial/ethnic differences in BP response to RAS inhibitor monotherapy are of questionable significance, particularly in light of the common need for combination therapy to achieve the BP goal in this population. For example, to achieve the BP target (mean arterial pressure 102-107 or ,92 mm Hg) in the African American Study of Kidney Disease and Hypertension , an average of 3 antihypertensive agents were required. 30 Current treatment guidelines 11, 17 acknowledge that the addition of antihypertensives such as diuretics or CCBs to RAS inhibitor therapy can help lessen or eliminate racial/ethnic disparities in BP-lowering effects. In our post hoc analysis, the use of a diuretic with an ARB was effective in controlling BP in African Americans, although our data suggest that this combination may not have entirely negated racial/ethnic differences. Of note, as per the recently updated ISHIB consensus statement, 11 the combination of a RAS inhibitor plus diuretic is one of the preferred options for the treatment of African Americans whose BP is .15/10 mm Hg above the target. 11 Our study population was representative of the general hypertensive population, although African Americans in our study did not have higher baseline MSSBP values relative to the whites. The younger age of African Americans vs the whites (;5 years) may have contributed to this finding.
Hypertension rarely exists in isolation and is often observed with a constellation of other risk factors such as obesity, dyslipidemia, diabetes, and renal disease, thus dramatically increasing the risk of developing cardiovascular events. 31 Therefore, the potential beneficial and harmful effects of selected antihypertensive therapies on concomitant cardiovascular, renal, and metabolic conditions must be considered in concert with traditional concerns (eg, likelihood of drug interactions, patient's individual risk profile, ability to access medication, and race/ethnicity). 32 The Seventh Report of the Joint National Committee (JNC 7) guidelines describe compelling indications for various antihypertensive agents, 17 and the recently updated ISHIB consensus statement 11 provide specific recommendations regarding advantages and disadvantages of antihypertensive classes in African Americans. These latter guidelines report that the benefits of RAS inhibitors in patients with a variety of comorbidities (eg, renal disease, diabetes, and congestive heart failure) extend to African Americans. Thus, RAS inhibitor combinations are appropriate for high-risk patients such as those enrolled in VITAE.
The recent reevaluation of the ALLHAT study (N = 42,418 high-risk hypertensives; 15,094 of whom were black) 33 has reemphasized the use of diuretics as first-line therapy, despite the potential for negative metabolic effects. In ALLHAT, 11.6% of the chlorthalidone group developed levels of fasting glucose consistent with diabetes mellitus ($125 mg/dL) after 4 years. This represented a significantly greater proportion of patients compared with the amlodipine (9.8%; P = 0.01) and lisinopril groups (7.8%; P , 0.001). The positive American Journal of Therapeutics (2013) 20 (1) www.americantherapeutics.com if needed) in hypertensive patients at high cardiovascular risk. 24 In Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research, the administration of valsartan in combination with other antihypertensive agents, including hydrochlorothiazide in about one-third of patients, reduced the risk of new-onset diabetes by 14% over non-ARB therapy (P , 0.001) in patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors. 25 Further, metaanalysis of data from 13 randomized, controlled trials demonstrated the protective effect of RAS inhibitors on the development of new-onset diabetes [26% reduction vs placebo or other agents (P , 0.001)]. 34 Thus, certain antihypertensive agents may be prodiabetic vs protective, making the selection of combination antihypertensive therapy very important, particularly in high-risk patients (eg, those who are obese, prediabetic, and/or have the cardiometabolic syndrome), regardless of race/ethnicity. The use of valsartan in combination with a diuretic in African Americans (and whites) requiring initiation of therapy with 2 agents has the potential to mitigate the negative metabolic effects of diuretic therapy.
As mentioned earlier, our study was not designed to compare the racial/ethnic differences in antihypertensive efficacy, metabolic parameters, or AE rates, and thus no definitive conclusions can be drawn in this regard. Interpretation of our results is also limited by the short study duration (16 weeks), which did not allow monitoring for development of diabetes. Nevertheless, the metabolic data do show a protective effect of valsartan when added to a diuretic. It should be noted that amlodipine was only added to hydrochlorothiazide at week 8 and that the full dose (10 mg) was only administered for 4 weeks (ie, weeks [12] [13] [14] [15] [16] . The duration of this combination/dose was likely adequate to accurately reflect its BP-lowering effect, as it was previously shown to plateau at 4 weeks. 35 CONCLUSIONS Valsartan/hydrochlorothiazide was as effective as amlodipine/hydrochlorothiazide in reducing the BP in obese, hypertensive African Americans and better than amlodipine/hydrochlorothiazide in whites. In both racial/ethnic subgroups, the addition of valsartan to hydrochlorothiazide reduced the negative metabolic effects associated with thiazide therapy.
